2013

2013

2013

2012

2012

2012

2012

2011

2011

2011

2011

2011

2011

2011

2011

Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G.Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat. 2011 Feb; 126(1): 109-17. Epub2010 Dec 29.

2010

Ihnen M, Wirtz RM, Kalogeras KT, Milde-Langosch K, Schmidt M, Witzel I, Eleftheraki AG, Papadimitriou C, Jänicke F, Briassoulis E, Pectasides D, Rody A, Fountzilas G, Müller V. Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer. Br J Cancer. 2010 Sep 28;103(7):1048-56.

2010

Schröder C, Schumacher U, Müller V, Wirtz RM, Streichert T, Richter U, Wicklein D, Milde-Langosch K. The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Cancer. 2010 Jun;46(9):1650-60. Epub 2010 Mar 11.

2010

Witzel ID, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, Mahner S, Zu Eulenburg C, Jänicke F, Müller V. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. J Cancer Res Clin Oncol. 2010 Mar 4.

2010

Croner RS, Wirtz R, Lausen B, Prokosch HU, Rödel C, Rödel F, Naschberger E, Wein A, Brückl WM, Hartmann A, Hohenberger W, Stürzl M – Prospective evaluation of predictive and prognostic molecular markers in colorectal carcinomas. J Clin Oncol 28, 2010 (suppl; abstr e14114) 

2010

Atmaca A, Steinmetz K, Pauligk C, Wirtz R, Homann N, Hofheinz R, Petry C, Altmannsberger HM, Jäger E, Al-Batran S – Validation of tumoral matrix-metalloproteinase-9 (MMP-9) mRNA expression as a molecular prognostic factor for metastatic gastroesophageal cancer . J Clin Oncol 28:15s, 2010 (suppl; abstr 4017)

2010

Psyrri D, Kronenwett R, Timotheadou E, Wirtz RM, Onyenadum A, Pentheroudakis GE, Papadimitriou CA, Razis E, Economopoulos T, Fountzilas G – Evaluation of the prognostic value of ube2c mrna levels in early breast cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 10570)

2009

Sinn B, Darb-Esfahani S, Wirtz R, Faggad A, Weichert W, Budczies J, Sehouli J, Braicu E, Dietel M, Denkert C – Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue – Virchows Arch. 2009 Nov 13.

2009

Pentheroudakis G, Kostadima L, Dova L, Georgiou I, Tzavaras T, Vartholomatos G, Wirtz RM, Fountzilas G, Malamou-Mitsi V, Pavlidis N – A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer – Neoplasma. 2010;57(1):47-54.

2009

Faggad A, Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, Müller BM, Wirtz RM, Dhekerov R, Weichert W, Sinn B, Mucha C, Eldin Elwali N, Schäfer R, Dietel M, Denkert C – Prognostic significance of Dicer expression in ovarian cancer – Link to global microRNA changes and estrogen receptor expression – Journal of Pathology 2009

2009

Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D – MMP9 but not EGFR, MET, ERCC1, and P53 is associated with response to concomitant Radiotherapy, cetuximab and weekly Cisplatin in patients with locally advanced head and neck cancer – J of Oncology 2009

2009

Pentheroudakis G, Angouridakis N, Wirtz R, Nikolaou A, Kalogeras KT, Pavlidis N, Fountzilas G – Transcriptional Activity of Human Epidermal Growth Factor Receptor Family and Angiogenesis Effectors in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma and Correlation with Patient Outcome – J Oncol. 2009;2009:854127. Epub 2009 Oct 7.

2009

Schröder C, Schumacher U, Fogel M, Feuerhake F, Müller V, Wirtz RM, Altevogt P, Krenkel S, Jännike F, Milde-Langosch K – Expression and prognostic value of L1-CAM in breast cancer. Oncology Reports 22: 1109-1117, 2009

2009

Zamagni C, Wirtz RM, De Iaco P, Veltrup E, Sehouli J, Dietel M, Rosati M, Denkert C, Martoni A – Estrogen receptor 1 mRNA predicts survival after neoadjuvant chemotherapy in ovarian cancer – determination by array and kinetic PCR in fresh tissue biopsies. Endocrine Relat Cancer 2009 Sep 11. [Epub ahead of print]

2009

Darb-Esfahani S, Wirtz RM, Sinn B, Budczies J, Noske A, Weichert W, Faggad A, Scharff S, Sehouli J, Oskay-Özcelik G, Martoni A, De Iaco P, Dietel M, Zamagni C, Denkert C – Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma – determination by kinetic PCR in formalin fixed tissue. Endocrine Relat Cancer 2009 Aug 12. [Epub ahead of print]

2009

Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Röske A, Müller B, Dietel M, Denkert C – IMP3 expression in human ovarian cancer is associated with improved survival. Int J Gynecol Pathol. 2009 May;28(3):203-10.

2009

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Noske A, Weichert W, Buckendahl AC, Budczies J, Müller BM, Elwali NE, Dietel M, Denkert C – Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology. 2009 May;54(6):657-66.

2009

Papaxoinis G, Pectasides D, Wirtz RM, Kotoula V, Papadimitriou C, Gogas H, Aravantinos G, Skarlos D, Kalogeras KT, Fountzilas G – Prognostic significance of PI3K mRNA expression in patients with operable high-risk breast cancer- J Clin Oncol 27:15s, 2009 (suppl; abstr 577)

2009

Pauligk C, Wirtz R, Steinmetz K, Hartmann JT, Homann N, Hofheinz RD, Petry C, Altmannsberger HM, Jäger E, Al-Batran S – Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) mRNA expression in patients with metastatic gastric cancer receiving first-line chemotherapy – J Clin Oncol 27:15s, 2009 (suppl; abstr 4547)

2009

Kronenwett R, Stropp U, Briasoulis E, Gehrmann M, Razis E, Hennig G, Bafaloukos D, Wirtz RM, Economopoulos T, Fountzilas G – Utility of a multigene prognostic algorithm in combination with TP53 expression for prediction of benefit from adjuvant taxane-containing chemotherapy in node-positive breast cancer patients – J Clin Oncol 27:15s, 2009 (suppl; abstr 593)

2009

Wirtz RM – Die Krux mit der Bestimmung des Hormonrezeptors – Problems when determining the hormone receptor status – mammazoneMAG May 2009

2009

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Weichert W, Noske A, Budczies J, Müller BM, Buckendahl AC, Röske A, Eldin Elwali N, Dietel M, Denkert C. Topoisomerase II alpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol. 2009 Apr;22(4):579-88. Epub 2009 Mar 6.

2009

Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Roedel F, Dimmler A, Dorlaque L, Hohenberger W, Hahn EG, Brueckl WM — Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal cancers and their synchronous liver metastases – Anticancer Res 2009Jan; 29(1):67-74.

2008

Papadimitriou CA, Kalogeras KT, Wirtz RM, Briasoulis E, Hennig G, Vourli G, Stropp U, Gogas H, Galani E, Samantas E, Makatsoris T, Fountzilas G – ] Elevated mRNA expression of herstatin predicts poor outcome in patients with high-risk early breast cancer. A possible molecular predictor of treatment benefit in the context of a Hellenic cooperative oncology group trial. SABCS 2008 #6066

2008

Kronenwett R, Kalogeras KT, Stropp U, Weber K, Dafni U, Gehrmann M, Pectasides D, von Toerne C, Papakostas P, Wirtz RM, Fountzilas G – [6044] Prognostic algorithm identified in node-negative early breast cancer patients predicts outcome also in node-positive patients treated with adjuvant chemotherapy. SABCS 2008 #6044

2008

Ihnen M, Müller V, Wirtz RM, Milde-Langosch K, Witzel I, Lisboa BW, Jänicke F – Prediction of chemotherapy response in breast cancer by using a four-gene panel including osteopontin, activating leukocyte cell adhesion molecule (ALCAM), HER2 and estrogen receptor (ER). SABCS 2008 #2033

2008

Loibl S, Müller B, Roller M, Kronenwett R, Darb-Esfahani S, Komor M, von Toerne C, Wirtz R, von Minckwitz G, Denkert C – Local versus central HER2 immunohistochemistry correlates with kinetic RT-PCR but only central immunohistochemistry and RT-PCR predict pathological complete response: results from the neoadjuvant multicenter GeparTrio trial. SABCS 2008 #1070

2008

Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G – Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer. 2008 Dec 2;99(11):1775-85. Epub 2008 Nov 4.

2008

Al-Batran S, Pauligk C, Wirtz R, Steinmetz K, Probst S, Hartmann JT, Hofheinz R, Homann N, Altmannsberger HM, Petry C, Jäger E – The expression of the epidermal growth factor receptor (EGFR) and related molecules and their impact on survival in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO. Gastrointestinal Cancer Symposium 2008

2008

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. – Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat. 2008 Jul 31. [Epub ahead of print]

2008

Pauligk C, Wirtz RM, Steinmetz K, Probst S, Hartmann JT, Hofheinz R, Homann N, Altmannsberger HM, Petry C, Jäger E, Al-Batran S – The prognostic role of the epidermal growth factor receptor (EGFR) in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO. J Clin Oncol 26: 2008 (May 20 suppl; abstr 22033)

2008

Fountzilas G, Wirtz RM, Skarlos P, Dafni U, Pectasides D, Briasoulis E, Bafaloukos D, Xanthakis I, Gehrmann M, Kalogeras KT – Molecular classification based on only four genes identifies basal-like subtypes in high-risk breast cancer patients. J Clin Oncol 26: 2008 (May 20 suppl; abstr 11103)

2008

Zamagni C, Wirtz RM, Sinn B, De Iaco P, Darb-Esfahani S, Rosati M, Dietel M, Massari F, Martoni AA, Denkert C – Estrogen receptor 1 mRNA expression as a strong prognostic factor in epithelial ovarian cancer patients treated with chemotherapy in the adjuvant and neoadjuvant setting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 16547)

2008

Papadimitriou C, Wirtz RM, Economopoulos T, Samantas E, Papakostas P, Gogas H, Razis E, Lianos E, Aravantinos G, Fountzilas G – Differential EGFR and VEGFR mRNA expression in two subtypes of basal-like breast cancer identified by molecular classification. J Clin Oncol 26: 2008 (May 20 suppl; abstr 22092)

2008

Al-Batran S, Wirtz RM, Pauligk C, Steinmetz K, Probst S, Hartmann JT, Hofheinz R, Altmannsberger HM, Petry C, Jäger E – Association of elevated matrix metalloproteinase-9 (MMP-9) mRNA expression levels with resistance to chemotherapy and survival in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4544)

2008

Brueckl WM, Schoeberl A, Wirtz RM, Murray S, Hahn EG, Wiest GH – Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol. 2008 Mar;3(3):314-6.

2008

Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, Lisboa BW, Jänicke F, Milde-Langosch K – Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat. 2008 Jan 3; [Epub ahead of print]

2007

Niesporek S, Weichert W, Sinn B, Röske A, Noske A, Buckendahl AC, Wirtz R, Sehouli J, Koensgen D, Dietel M, Denkert C. – NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression. Verh Dtsch Ges Pathol. 2007;91:243-9. .

2007

Fountzilas G, Skarlos D, Wirtz RM, Dafni U, Stropp U, Pectasides D, Papakostas P, Markopoulos C, Karapanagiotis K, Polichronis A, Timotheadou E, Grimani I, Samantas E, Kosmidis P, Kalogeras KT – Prognostic value of both HER-2 and VEGF-A mRNA over-expression in primary tumors of high-risk breast cancer patients – SABCS 2007 #6007

2007

Lenhard MS, Wirtz RM, Hasmueller S, Rueckert S, Ditsch N, Ruehl I, Kahlert S, Bauerfeind I, Untch M, on Behalf of the Participating Centers – Relation of intratumoral B-cells and response to neoadjuvant chemotherapy. SABCS 2007 #2110

2007

Rueckert S, Wirtz R, Lenhard M, Hasmueller S, Ditsch N, Ruehl I, Kahlert S, Bauerfeind I, Untch M – Microtubule-associated protein tau is a marker of pathological complete response in Her-2/neu positive neoadjuvant treated breast cancer patients – SABCS 2007 #2016

2007

Wirtz R.M. – Molekularbiologische Ansätze für eine verbesserte Diagnostik und Selektion gezielter Therapieansätze – 27. Jahrestagung der deutschen Gesellschaft für Senologie – Lübeck Juni 2007 (Oral Presentation)

2007

Wirtz RM, Lenhard MS, Rückert S, Hasmüller S, Konecny G, Fasching P, Euting H, S. Claas S, Ditsch N, Rühl I, Bauerfeind I, Untch M – Determination of Her-2/neu status by semi-automated qRT-PCR in core needle biopsy FFPE tissues, correlation with standard IHC / FISH technology and response to neoadjuvant Trastuzumab-containing regimen (TECHNO-Trial) – AACC 2007

2007

Gehrmann M, Wirtz RM , von Törne C, Stropp U, Schmidt M – Concordance between protein and RNA tissue concentration of estrogen receptor alpha (ER) in fresh frozen as well as formalin fixed paraffin embedded breast tumors – AACC 2007

2007

Gehrmann M, Wirtz RM , von Törne C, Stropp U, Schmidt M – Breast cancer prognosis in node negative early breast cancer – AACC 2007

2007

Zamagni C, Wirtz RM, De Iaco P, Altimari A, Roth K, Rosati F, Rosati M, Massari F, Cacciari N, Martoni AA – Response to primary chemotherapy (CHT) in advanced epithelial ovarian cancer (EOC) patients (pts) and molecular characterization of CHT-resistant tumor cell populations: Findings from the Arianna 02 Project. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 16059

2007

Brueckl WM, Wirtz RM, Croner RS, Boxberger F, Papadopoulos T, Kirchner T, Hahn EG, Hohenberger W, Wein A – Evaluation of Spondin-1 as a predictive marker for palliative 5-FU based chemotherapy in metastatic colorectal cancer – Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4112.

2007

Briasoulis EC, Papamichael D, Tzachanis D, Christodoulou C, Samantas E, Razis E, Papakostas P, Bakoyiannis C, Wirtz RM, Kalogeras KT; – Predictive value of EGFR mRNA levels assessed by quantitative RT-PCR in primary tumors of patients treated with cetuximab for metastatic colorectal cancer – Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4121.

2007

Witzel I, Milde-Langosch K, Ihnen M, Lisboa B, Wirtz R, Müller V – Correlation between protein and RNA tissue concentration of biologic relevant factors in breast cancer – TRAFO 2007 #023

2007

Niesporek S., Weichert W., Sinn B., Röske A., Noske A., Buckendahl A.C., Wirtz R.M., Sehouli J., Koensgen D., Dietel M., Denkert C. – NF-κB subunit p65/RelA expression is an independent prognostic factor in human ovarian cancer and is linked to COX-2 overexpression in vivo and in vitro – AACR 2007 #2514

2007

Wirtz R.M. – Biomarker zur Prädiktion der Wirkung zielgerichteter Medikamente – 1. Forschungswerkstatt Onkologie der Bayer HealthCare AG – Köln 01 March 2007 (Oral Presentation and Publication). Der Onkologe 13 (2007), Suppl. 1, Springer Verlag.

2007

Linardou H., Fountzilas G., Wirtz R.M., Malamou-Mitsi V., Stropp U., Aravantinos G., Pectasides D., Gogas H., Grimani I., Koutras A., Dafni U., Hennig G., Skarlos D. and Kalogeras K.T. – Prognostic value of VEGF-A mRNA expression in primary tumors of high-risk breast cancer patients: a Hellenic Cooperative Oncology Group study. TAT 2007 P703.

2006

Lenhard M.S., Wirtz R.M., Rückert S., Hasmüller S., Ditsch N., Rühl I., Bauerfeind I., Untch M. – Correlation of quantitative Her-2/neu gene expression (TaqMan PCR) with standard immunohistochemistry and fluorescence in situ hybridization in core needle biopsies. SABCS 2006 #4009.

2006

Rueckert S., Wirtz R.M., Lenhard M., Ruehl I., Hasmueller S., Ditsch N., Bauerfeind I., Untch M. – Response prediction in neoadjuvant trastuzumab treated HER-2/neu-positive breast cancer by quantitative RT-PCR analysis of FFPE tissue. SABCS 2006 #3042.

2006

Ruehl I.M., Wirtz R.M., Lenhard M., Hasmueller S., Rueckert S., Ditsch N., Kahlert, Bauerfeind I., Untch M. – Significance of cyclin D1 expression and amplification status in paraffin-embedded tissue of Her2/neu positive breast cancer patients treated in a neoadjuvant trastuzumab-containing protocol (TECHNO-trial). SABCS 2006 #3027.

2006

Fountzilas G., Wirtz R.M., Skarlos D.V., Stropp U., Dafni U., Briasoulis E., Pectasides D., Gogas H., Kalofonos H.P., Papakostas P., Bafaloukos D., Economopoulos T., Aravantinos G., Kalogeras K.T., Dimopoulos M.A. – Prognostic value of DNA and RNA expression of HER-2 compared to that of HER-2 protein levels in primary tumors of high-risk breast cancer patients. SABCS 2006 #2032.

2006

Hasmueller S., Wirtz R.M., Lenhard M., Ditsch N., Rueckert S., Ruehl I., Bauerfeind I. and Untch M. – Amplification of Her2/neu and transcription levels of Her2/neu mRNA measured by RT-PCR in paraffin-embedded core-needle biopsies as predictive markers for response to neoadjuvant therapy with trastuzumab, epirubicin, cyclophosphamide and paclitaxel in early breast cancer (TECHNO-Trial). SABCS 2006 #1042.

2006

Wirtz R.M. – New Perspectives in the characterization and in the monitoring of ovarian cancer patients – Therapeutic Progresses and Perspectives in Ovarian Cancer – Bologna 01 Dec 2006 (Oral Presentation)

2006

Wirtz R.M. – Genetic alterations predicting the response of high-risk breast cancer patients to paclitaxel-based adjuvant chemotherapy – Breast Cancer: From Gene to Therapy – Thessaloniki 18 Nov 2006 (Oral Presentation)

2006

Kostadima L., Pentheroudakis G., Fountzilas G., Dimopoulos M., Pectasides D., Gogas H., Stropp U., Christodoulou C., Samantas E., Wirtz R., Hennig G., Bafaloukos D., Arapantoni P., Kalofonos H., Papakostas P., Economopoulos T., Bamias A., Pavlidis N. -Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat 2006; 100(2):161-7.

2006

Brueckl W.M., Wirtz R., Croner R.S., Boxberger F., Schuppert A., Meyer T., Papadopoulos T., Hahn E.G., Hohenberger W., Wein A. – Microarray based response prediction to palliative chemotherapy in metastatic colorectal carcinoma – HOX and MMP gene family members seem to be promising candidates. ESMO 2006 #860P.

2006

Brueckl W.M., Wirtz R., Croner R.S., Boxberger F., Gentner B., Munnes M., Schuppert A., Meyer T., Papadopoulos T., Hahn E.G., Hohenberger W., Wein A. – Hox- and MMP- gene family members are expressed in freshly frozen and paraffin embedded metastatic colorectal carcinoma – implication for response prediction to a palliative 5-FU containing chemotherapy. DKK 2006.

2006

Fountzilas G., Angouridakis N., Wirtz R.M., Claas S., Nikolaou A., Kalogeras K.T. – Prognostic value of VEGFC, HER2 and HER3 gene expression in recurrent squamous cell head and neck tumors -Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 5538.

2005

Brueckl W. M., Croner R. S., Hohenberger W., Munnes M., Wirtz R., Zeittraeger I., Meyer T., Papadopoulos T., Hahn E. G., Wein A. – Response prediction to a 5-Fluorouracil based first-line palliative chemotherapy for metastatic colorectal cancer by gene expression profiling of liver metastases using DNA microarrays- Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 3558.

2005

Fountzilas G., Stropp U., Razis E., Wirtz R., Skarlos D., Gogas H., Pavlidis N., Kalofonos H. P., Pectasides D., Dimopoulos A. M. – Genetic alterations predicting the response of high risk breast cancer patients to Taxol-based adjuvant chemotherapy- Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 9574.

2005

Wirtz R.M. – Molekulare Klassifizierung von Tumoren durch kombinierte DNA/RNA Analyse im Paraffingewebe – 25 th Annual Meeting of the German, Austrian an Suisse Breast Cancer Society – Stuttgart Sep 2005 (Oral Presentation)

2000

Wirtz R., Behrens J. and Birchmeier W. – Interaction of b-catenin with SWI/SNF factors. Keystone Symposia 2000.

1998

Behrens J., Jerchow B-A., Würtele M., Grimm J.,Asbrand C., Wirtz R., Kühl M., Wedlich D. and Birchmeier W. – Functional interaction of an axin homolg, conductin, with b-catenin, APC, and GSK3b. Science 1998; 280: 485-640.

1997

Brix K., Wirtz R. and Herzog V. – Paracrine interation between hepatocytes and macrophages after extrathyroidal proteolysis of thyroglobulin. Hepatology 1997; 26: 1232-1240.